News
Novo Nordisk: Is the Ozempic Hype Train Finally Slowing Down?
Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug Wegovy, going down from May’s 21% growth projection to just a 14% sales increase throughout 2025.
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
Novo Nordisk (NVO) stock draws mixed views from Wall Street analysts after the obesity drugmaker cut its 2025 outlook for the ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
In a market note, the investment firm said it downgraded Novo Nordisk A/S (NYSE:NVO) to “neutral” from “buy” previously and ...
Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
U.S.-listed shares of Novo Nordisk (NVO) fell sharply for a second straight day Wednesday, this time after Bank of America ...
Despite a steep 65% drop from its all-time high of 145.99 a share in the prior 12 months, Novo Nordisk remains one of the most operationally sound businesses on the planet. As an investor, you are ...
Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback